

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 28-03-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 13-1-2007 TO BE PUBLISHED ON 28-3-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

13/2007	08-01-2007 Clariant International Ltd. Switzerland. (Priority 10-01-2006 Germany)	“Fluorous telomeric compounds and polymers containing same”
14/2007	Casale Chemicals S.A. Switzerland. (Priority 10-01-2006 EP)	“Apparatus for producing synthesis gas”
15/2007	Millennium Pharmaceuticals, Inc. USA. (Priority 13-11-2002 US) Divisional	“CCR1 antagonists and compositions thereof”
16/2007	09-01-2007 Bajaj Auto Ltd. India. (Priority 10-01-2006 India)	“Rocker arm assembly for an internal combustion engine”
17/2007	Emer S.P.A. Italy.	“Electromagnetic powered injection valve for gaseous fuels”
18/2007	Boehringer Ingelheim International GmbH. Germany (Priority 11-01-2006 EP)	“Crystalline form of 1’ –(1-methylethyl)-4’-methoxyphenyl methyl]-5’-methyl-1H-pyrazol-3’-O-b-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments”
19/2007	Glaxo Group Limited. United Kingdom. (Priority 11-01-2006 GB)	“Immunoglobulins”
20/2007	Aventis Pharma S.A. France. (Priority 23-01-2006 France)	“Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors”
21/2007	10-01-2007 AstraZeneca AB. Sweden. (Priority 17-01-2006 US)	“Chemical Compounds”
22/2007	Janssen Pharmaceutica N.V. Belgium. (Priority 10-01-2006 US)	“Urotensin II receptor antagonists”
23/2007	Novartis AG. Switzerland. (Priority 13-01-2006 USA)	“Compositions and methods of use for antibodies of dickkopf-1”
24/2007	Irm LLC. Bermuda. (Priority 13-01-2006 US)	“Methods and compositions for treating allergic diseases”

25/2007	Generex Pharmaceuticals Inc. Canada. (Priority 06-10-2006 Canada) <u>11-01-2007</u>	“Composition and method for raising blood glucose level”
26/2007	Wyeth. USA. (Priority 13-01-2006 USA)	“Method for the treatment of cognitive dysfunction”
27/2007	I.B.S. International Biomedical Systems S.R.L. Italy. (Priority 13-01-2006 Italy)	“Endovascular prosthesis and relating manufacturing procedure”
28/2007	DSM IP Assets B.V. Netherlands. (Priority 11-01-2006 EP)	“Process for the production of a monolayer composite article, the monolayer composite article and a ballistic-resistant article”
	<u>12-01-2007</u>	
29/2007	FMC Australasia Pty. Ltd. Australia. (Priority 12-01-2006 Australia)	“Cables”
30/2007	FMC. Australasia Pty. Ltd. Australia. (Priority 12-01-2006 Australia)	“Granules for providing a barrier”
	<u>13-01-2007</u>	
31/2007	Ntera, Inc. USA. (Priority 13-01-2006 US)	“Active matrix electrochromic display”
32/2007	Ntera Inc. USA (Priority 13-01-2006 US)	“Reflective display devices”
33/2007	Ntera Inc. USA. (Priority 13-01-2006 US)	“An electrochromic device employing gel or solid polymers having specific channel direction for the conduction of ions”
34/2007	Syngenta Participations AG. Switzerland. (Priority 16-01-2006 EP)	“Novel insecticides”
35/2007	N.V. Organon. Netherlands. (Priority 16-01-2006 EP)	“6-Phenyl-1H-Imidazo[4,5-c]Pyridine-4-Carbonitrile Derivatives”
36/2007	Wyeth. USA. (Priority 13-01-2006 USA)	“Treatment of substance abuse”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

937/2000	Syngenta Participations AG. Switzerland	“Method for improving plant growth by applying a compound selected from the class of neonicotinoid” (Class: A01N, 51/00)	139226
		Method for improving plant growth by applying a compound selected from the class of neonicotinoid thiamethotan, clothianidin, imidacloprid, acetamiprid.	
786/2002	Merck Patent GmbH, West Germany	“Substituted aminomethyl chroman for the treatment o side effects of neuroleptics” (Class: A61K, 31/15, C07D, 417/12)	139227
		Comprises substituted aminomethyl chroman and at least one anti-parkinsonian drug, in combination with one or more pharmaceutically acceptable excipients for the treatment o side effects of neuroleptics.	

